TY  - JOUR
AU  - Blanco, Francisco J
AU  - Rubio-Romero, Esteban
AU  - Sanmartí, Raimon
AU  - Díaz-Torné, César
AU  - Talavera, Pablo
AU  - Dunkel, Jochen
AU  - Naredo, Esperanza
AU  - SONAR Study Team
PY  - 2018
DO  - 10.1016/j.reuma.2018.07.009
UR  - http://hdl.handle.net/10668/12971
T2  - Reumatologia clinica
AB  - To assess the effectiveness and safety of certolizumab pegol (CZP) in Spanish patients with RA. SONAR (NCT01526434), a 12-week, open-label, prospective, observational, multicenter study. Patients with active RA for ≥3 months, according to ACR...
LA  - en
KW  - Anti-TNF
KW  - Artritis reumatoide
KW  - Certolizumab pegol
KW  - Ecografía
KW  - Observacional
KW  - Observational
KW  - Rheumatoid Arthritis
KW  - Ultrasound
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antirheumatic Agents
KW  - Arthritis, Rheumatoid
KW  - Certolizumab Pegol
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Patient Reported Outcome Measures
KW  - Prospective Studies
KW  - Severity of Illness Index
KW  - Spain
KW  - Tumor Necrosis Factor-alpha
KW  - Ultrasonography, Doppler
KW  - Young Adult
TI  - Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.
TY  - research article
VL  - 16
ER  -